Tyler Ehler - I Mab Senior Relations
| IMAB Stock | USD 0.94 0.02 2.08% |
Executive
Tyler Ehler is Senior Relations of I Mab
| Address | 2440 Research Boulevard, Rockville, MD, United States, 20850 |
| Phone | 240 745 6330 |
| Web | https://ir.i-mabbiopharma.com |
I Mab Management Efficiency
The company has return on total asset (ROA) of (0.2925) % which means that it has lost $0.2925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7172) %, meaning that it created substantial loss on money invested by shareholders. I Mab's management efficiency ratios could be used to measure how well I Mab manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.59. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, I Mab's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 5.2 B, whereas Non Current Assets Total are forecasted to decline to about 262.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kathryn Romano | Krystal Biotech | 42 | |
| Karen Weisbach | Kymera Therapeutics | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Conor CPA | Shattuck Labs | N/A | |
| Juliet BA | Kymera Therapeutics | N/A | |
| Jason Radford | BeiGene | 42 | |
| Mads Bodenhoff | Ascendis Pharma AS | N/A | |
| Stephane Paquette | Krystal Biotech | N/A | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| Ram Kamineni | Krystal Biotech | N/A | |
| Jennifer McDonough | Krystal Biotech | N/A | |
| Lauren MBA | Immunovant | N/A | |
| MD MBA | Immunovant | 56 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Scott Gangloff | Akero Therapeutics | 50 | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Mark Levine | Immunovant | 51 | |
| Kelli MS | Shattuck Labs | N/A | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Pr MD | Apellis Pharmaceuticals | N/A | |
| Christine Blodgett | Immunovant | N/A | |
Management Performance
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.29 |
I Mab Leadership Team
Elected by the shareholders, the I Mab's board of directors comprises two types of representatives: I Mab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IMAB. The board's role is to monitor I Mab's management team and ensure that shareholders' interests are well served. I Mab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, I Mab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CLP Esq, COO CFO | ||
| Louie MD, Interim Officer | ||
| Richard MBA, COO CFO | ||
| Weiming Tang, Executive Officer | ||
| Jerry Wang, CoFounder Officer | ||
| Cheng Li, Chief Officer | ||
| Skelton Joseph, Chief Officer | ||
| John MD, Chief Officer | ||
| XiYong MBA, Director CEO | ||
| Tianyi Zhang, Vice Relations | ||
| Raj Kannan, CEO Director | ||
| Jingwu MD, Founder Chairman | ||
| Ivan Zhu, Chief Officer | ||
| Min Yin, Senior Operations | ||
| Phillip MD, Chief Officer | ||
| Gigi Feng, Chief Officer | ||
| Fernando Salles, Senior Development | ||
| Claire Xu, Head site | ||
| Tyler Ehler, Senior Relations |
IMAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is I Mab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (49.38) % | ||||
| Current Valuation | (104.02 M) | ||||
| Shares Outstanding | 77.58 M | ||||
| Shares Owned By Insiders | 11.16 % | ||||
| Shares Owned By Institutions | 31.00 % | ||||
| Number Of Shares Shorted | 591.16 K | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 21.93 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share 0.043 | Quarterly Revenue Growth (0.62) | Return On Assets (0.29) | Return On Equity (0.72) |
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.